Afatinib is an orally available agent with increased efficacy compared with chemotherapy, making it an attractive option for advanced NSCLC in those with adenocarcinoma and common EGFR mutations (Sequist et al., 2013; Wu et al., 2014). This evidence concerns the gene EGFR and adenocarcinoma.